NCT02326805View on ClinicalTrials.gov

PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

June 3, 2015

Primary Completion Date

November 30, 2018

Study Completion Date

July 20, 2022

Conditions
Stage I Prostate Adenocarcinoma AJCC v7Stage II Prostate Adenocarcinoma AJCC v7
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Placebo Administration

Given SC

BIOLOGICAL

Rilimogene Galvacirepvec

Given SC

Trial Locations (7)

20892

NCI - Center for Cancer Research, Bethesda

21224

Johns Hopkins Bayview Medical Center, Baltimore

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

90048

Cedars Sinai Medical Center, Los Angeles

92103

UC San Diego Medical Center - Hillcrest, San Diego

92663

Hoag Memorial Hospital, Newport Beach

92868

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02326805 - PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance | Biotech Hunter | Biotech Hunter